Chemotherapy News and Research

Latest Chemotherapy News and Research

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Disabling a cancer-causing pathway and administering an immune-molecule-based mop-up therapy eradicated a specific type of breast tumor in mice, according to researchers in the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

SMC5/6 protein complex plays vital role in cancer suppression and premature ageing

A study conducted by the Spanish National Cancer Research Centre´s Genomic Instability Group, led by Óscar Fernández-Capetillo, describes for the first time in mammals, the role played by the SMC5/6 protein complex in cancer suppression and premature ageing. Mutations in these complexes, which were sensitive to chemotherapeutic agents, had been previously described in yeast cells, but their exact relationship with cancer or other diseases in mammals was unknown.

8 Oct 2015

Primasil innovation helps improve Paxman™ cooling cap

Collaboration between Primasil Silicones and its academic partner University of Huddersfield has enabled Paxman™ to bring relief to cancer patients undergoing chemotherapy by further reducing the risk of hair-loss during treatment.

From Paxman 7 Oct 2015

Three researchers recognised for their contributions to Australian medical research

Three top Walter and Eliza Hall Institute researchers have been recognised for their contributions to Australian medical research, with their election as fellows of the Australian Academy of Health and Medical Sciences.

7 Oct 2015

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

7 Oct 2015

Penn Medicine announces $375,000 in new grants to support BRCA-focused research projects

Penn Medicine's Basser Center for BRCA announced $375,000 in new grant funding to support BRCA-focused research projects across the nation. The grants are aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations.

7 Oct 2015

New diagnostic technology based on computer algorithms can quickly identify source of cancer

In by far the majority of cancer cases, the doctor can quickly identify the source of the disease, for example cancer of the liver, lungs, etc. However, in about one in 20 cases, the doctor can confirm that the patient has cancer—but cannot find the source. These patients then face the prospect of a long wait with numerous diagnostic tests and attempts to locate the origin of the cancer before starting any treatment.

7 Oct 2015

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

A recent publication, which received sustained media attention, claimed that most cancers are just “bad luck”. Its authors stated that only about one-third of cancer mutations are caused by known lifestyle or environmental factors.

6 Oct 2015

World Scientific publishes new book that covers all aspects of cancer care

Cervical, uterine and ovarian cancers are among the most common cancers affecting women, with a total of 1,087,000 new cases diagnosed worldwide in 2012.

1 Oct 2015

Neuroendocrine sequelae common after paediatric optic gliomas

Neuroendocrine sequelae are common following paediatric low-grade gliomas affecting the optic pathway, hypothalamus and suprasellar areas and are influenced by tumour location and treatment choice, a study shows.

1 Oct 2015

Weight training can make a big difference for breast cancer survivors

Weight training can be a big boost to breast cancer survivors who are trying to regain muscle and bone strength lost due to cancer treatment and physical inactivity, says a Florida State University researcher.

1 Oct 2015

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market.

1 Oct 2015

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Monteris Medical today announced recent data demonstrating that newly diagnosed brain tumor patients undergoing procedures with the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool, experienced improved outcomes.

1 Oct 2015

Patients with advanced lung cancer receive more than recommended number of radiation therapy

Almost half of patients with advanced lung cancer receive more than the recommended number of radiation treatments to reduce their pain, according to a new study published in the Journal of the National Cancer Institute.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Chemotherapy News and Research

Latest Chemotherapy News and Research

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

SMC5/6 protein complex plays vital role in cancer suppression and premature ageing

Primasil innovation helps improve Paxman™ cooling cap

Three researchers recognised for their contributions to Australian medical research

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Penn Medicine announces $375,000 in new grants to support BRCA-focused research projects

New diagnostic technology based on computer algorithms can quickly identify source of cancer

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

World Scientific publishes new book that covers all aspects of cancer care

Neuroendocrine sequelae common after paediatric optic gliomas

Weight training can make a big difference for breast cancer survivors

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Patients with advanced lung cancer receive more than recommended number of radiation therapy

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in